Diabetic Kidney Diseaseportada_kidney

Diabetes Kidney Disease is a major complication of diabetes and   affects about one-third of all adult diabetics. It is the name by which kidney disorders in people with diabetes are defined when control of blood glucose and other associated factors has not been adequate.

  • Diabetic nephropathy is completely asymptomatic until severe and often irreparable damage to kidney function occurs.
  • Due to diabetic nephropathy, about 30% of dialysis is performed..
  • Diabetic nephropathy is the leading cause of kidney transplantation in Western countries.
  • 1 in 3 adults with newly diagnosed type 2 diabetes also have diabetic nephropathy, demonstrating that the disease began to develop as diabetes progressed.
  • Early detection and treatment of diabetic nephropathy is essential to prevent further kidney damage.

Limitations of traditional Diabetes Kidney Disease

Tests in patients with type 2 diabetes consist of periodic blood and urine tests to detect inadequate early loss of protein in the urine (albuminuria) and impairment of kidney function. These tests are performed annually.

Sin título-3Nowadays the tests performed for the diagnosis of diabetic nephropathy are eGFR (Estimated Glomerular Filtration Rate Analysis) and ACR (Albumin to Creatine Ratio) to quantify how the kidneys work in relation to albumin or creatine.

These tests cannot predict the risk of developing kidney disease and can be very variable, producing different and inconclusive results.
No current test predicts the risk of diabetic kidney nephropathy.

The PromarkerD test is able to predict the incidence of diabetic nephrology with higher odds ratios than eGFR or ACR.



Predicts four-year risk of Diabetes Kidney Disease

  • PromarkerD helps predict the risk of diabetes kidney disease  before damage occurs.
  • Predice una rápida reducción en la tasa de mortalidad por complicaciones de la diabetes tipo 2 en todas las definiciones clínicamente significativas de enfermedad renal diabética, independientemente de los factores de riesgo clínicos reconocidos.
  • Combines three biomarkers and three clinical variables, and generates an estimated risk of developing the disease.
  • Is the only independent predictor of diabetes kidney disease within four years, in patients with type 2 diabetes.
  • Generates an estimate of low, moderate or high risk of developing the disease.
  • Also diagnoses existing diabetes kidney disease that current test may miss.

Sensibility 86%, Specificity 78%, AUC 0.88


Prediction of incident diabetes kidney disease

  • The PromarketD test predicted incident diabetes kidney disease with a higher adjusted odds ration compare to eGFR and ACR.

Result Interpretation

Clinical stydy data show the PromarkedD test is an independent predictor of rapid eGFR decline in type 2 diabetes across clinically significant definitions of diabetes kidney disease. The PromarkerD test uses two cut-offs to define low, moderate and high risk of developing diabetes kidney disease in the next four years.